Lower-dose treatment might one day suit certain patients, but she said, "Researchers need strong clinical trials first." She outlined what would have to come together: studies testing lower doses directly rather than in theory, proof that the results hold up over years without significant weight re-gain, a clearer picture of who benefits most, consistent manufacturing standards, and regulatory review of the evidence
Blue Cross Blue Shield of Michigan GLP-1 Coverage Changes Explained Understanding the New Coverage Changes As of August 1, 2024, Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network (BCN) are altering their coverage for GLP-1 receptor agonists, which include popular weight loss medications like Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
This keeps the conversation grounded in health history, goals, and whether the option is appropriate for the person requesting it
Medco has chosen medicine therapy management (MTM) as the focus of new business development
